Glucoraphanin for Health & Longevity

Created on 11/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Glucoraphanin, a natural broccoli compound sold as a dietary supplement to switch on the body's own protective enzymes, works only after gut bacteria or an added plant enzyme turn it into sulforaphane, its active form; conversion varies greatly between people. A few studies backed by one food company suggest small improvements in liver enzyme levels and, in older adults, mental processing speed. Side effects appear mild; long-term effects remain unmeasured. (Full Review)

Protocol

Glucoraphanin-only capsules
30–60 mg/day
30 mg/day in the 12-week cognition trials; 60 mg/day for 24 weeks in the liver trial
Glucoraphanin plus myrosinase
Mustard-seed myrosinase
Doubled bioavailability; tablets dosed at about 2.2 µmol/kg/day of sulforaphane yield
Time of day
Once daily, morning or midday
Gut conversion greater during the day; slow conversion makes once-daily dosing practical
Time to effect
Liver enzymes
24 weeks
In adults with high-normal ALT
Processing speed
12 weeks
In healthy older adults
Pollutant excretion
Rapid
Urinary detoxification products of benzene and acrolein

Benefits

Contraindications
  • People with mustard allergy, for products containing mustard-seed myrosinase
  • Pregnant or breastfeeding women at supplement doses
  • People receiving chemotherapy or radiotherapy, unless their oncology team agrees
  • People with untreated hypothyroidism and iodine deficiency
Key Interactions
  • Proton pump inhibitors (omeprazole): higher, less predictable exposure
  • Oral antibiotics (amoxicillin): little sulforaphane from glucoraphanin-only products during a course
  • CYP1A2 substrates (caffeine, clozapine): possibly lower drug levels
  • UGT1A1 substrates (irinotecan): possibly faster drug clearance
  • Mustard-seed myrosinase (supplement): doubled exposure, possibly more gastrointestinal effects
  • Curcumin (supplement): additive protective-enzyme induction
Theoretical (inferred from mechanism)
  • Glucose-lowering drugs (metformin, insulin): additive glucose lowering and possible hypoglycemia
  • Acetaminophen: altered metabolism of uncertain direction
  • Chemotherapy and radiotherapy (doxorubicin): possibly reduced treatment efficacy
  • Other isothiocyanate supplements (sulforaphane): more gastrointestinal discomfort

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal discomfort and taste intolerance; thyroid suppression; insomnia, irritability and isolated seizure reports
  • Speculative: Protection of established tumors; pro-oxidant effects at high doses

Monitoring

Marker Target Why
ALT About 7–55 U/L Expected to change: fell in glucoraphanin trials
GGT About 8–61 U/L Expected to change: trended lower
LDL cholesterol No established target for glucoraphanin use; change from own baseline Expected to change: fell with high-glucoraphanin broccoli
Fasting glucose 70–99 mg/dL Expected to change modestly in prediabetes
HbA1c Not specified in the ER Paired with fasting glucose every 6 months
TSH 0.45–5.33 mIU/L Safety check: a rise prompts a pause
Free thyroxine Not specified in the ER Paired with TSH if abnormal
Drug level (narrow-margin CYP1A2 or UGT1A1 drugs) Not specified in the ER Detects under-dosing from faster drug clearance

Cadence: Baseline, then 12 weeks, then 24 weeks, then every 6–12 months while use continues; TSH repeated at 3 months in at-risk users

Qualitative Assessment

  • Gastrointestinal comfort (stool consistency, nausea, bloating)
  • Sleep quality and any new irritability
  • Mental processing speed and clarity in daily tasks
  • Mood and sense of energy